Janux Therapeutics (NASDAQ:JANX) Shares Up 8%

Shares of Janux Therapeutics, Inc. (NASDAQ:JANX) shot up 8% on Thursday . The company traded as high as $33.58 and last traded at $33.58. 439 shares were traded during trading, a decline of 100% from the average session volume of 227,858 shares. The stock had previously closed at $31.09.

A number of research firms recently weighed in on JANX. Evercore ISI began coverage on Janux Therapeutics in a research note on Tuesday, July 6th. They set an “outperform” rating and a $35.00 price target on the stock. Cowen began coverage on Janux Therapeutics in a research note on Tuesday, July 6th. They set an “outperform” rating on the stock. Zacks Investment Research downgraded Janux Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, September 9th. HC Wainwright started coverage on Janux Therapeutics in a research note on Tuesday, July 6th. They issued a “buy” rating and a $35.00 price objective for the company. Finally, Bank of America started coverage on Janux Therapeutics in a research note on Tuesday, July 6th. They issued a “buy” rating and a $35.00 price objective for the company. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. According to MarketBeat, Janux Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $35.00.

The firm’s fifty day moving average is $30.09.

Janux Therapeutics (NASDAQ:JANX) last released its earnings results on Tuesday, August 10th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.48). Sell-side analysts anticipate that Janux Therapeutics, Inc. will post -1.02 EPS for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in JANX. RA Capital Management L.P. bought a new position in shares of Janux Therapeutics in the second quarter valued at approximately $216,333,000. Citadel Advisors LLC bought a new position in Janux Therapeutics during the second quarter valued at $46,239,000. FMR LLC bought a new position in Janux Therapeutics during the second quarter valued at $45,997,000. BVF Inc. IL bought a new position in Janux Therapeutics during the second quarter valued at $29,358,000. Finally, Samsara BioCapital LLC bought a new position in Janux Therapeutics during the second quarter valued at $15,168,000. 59.46% of the stock is owned by institutional investors.

Janux Therapeutics Company Profile (NASDAQ:JANX)

Janux Therapeutics, Inc, a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2.

Recommended Story: Trading Stocks – What are percentage gainers?

Receive News & Ratings for Janux Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Janux Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.